Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Applications of Liquid Biopsy Webinar Series – Lung Cancer

ESMO-Webinar-Series-Liquid-Biopsy-in-Lung-Cancer-1000x250

Airs on 27 October 2021 at 16:00 CEST

Start date
27 Oct 2021
End date
27 Oct 2021
Live on
27 Oct 2021

Register now

This webinar aims to review and discuss data for liquid biopsy-based assessments as endpoints of antitumour activity in clinical trials, understand the potential and limitations of liquid biopsy-based tumour genomic profiling for patient stratification and detection of predictive biomarkers of response to therapy, and to discuss how tumour heterogeneity and evolution assessed via liquid biopsy assays may improve lung cancer treatment strategies.

The webinar will also offer the opportunity for real-time interaction between audience and experts.

Chair

Tony Mok

Speakers

Christian Rolfo, Maximilian Diehn

Programme

  • Welcome and Introduction, Prof. Tony Mok, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, SAR China  
  • Current Status of MRD and Plasma Monitoring for Resectable Lung Cancer, Prof. Christian Rolfo, Center for Thoracic Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, New York, NY, US
  • The Role of plasma-based cfDNA Testing in Management of EGFR or ALK Positive Lung Cancer, Prof. Tony Mok, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, SAR China
  • Novel Technology in Liquid Biopsy for Lung Cancer, Prof. Maximilian Diehn, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, US
  • Q&A 
  • Closing Remarks, Prof. Tony Mok, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, SAR China

Learning objectives

  • Understand the current status of minimal residual disease and plasma monitoring for resectable lung cancer 
  • Understand the role of plasma-based cfDNA testing in management of EGFR or ALK positive lung cancer
  • Understand novel technologies in liquid biopsy for lung cancer

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings